Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

BACKGROUND: Bladder cancer is the 7th cause of death from cancer in men and 10th in women. Metastatic patients have a poor prognosis with a median overall survival of 14 months. Until recently, vinflunine was the only second-line chemotherapy available for patients who relapse. Deregulation of the P...

Descripción completa

Detalles Bibliográficos
Autores principales: Pulido, Marina, Roubaud, Guilhem, Cazeau, Anne-Laure, Mahammedi, Hakim, Vedrine, Lionel, Joly, Florence, Mourey, Loic, Pfister, Christian, Goberna, Alejandro, Lortal, Barbara, Bellera, Carine, Pourquier, Philippe, Houédé, Nadine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816357/
https://www.ncbi.nlm.nih.gov/pubmed/29454321
http://dx.doi.org/10.1186/s12885-018-4059-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816357/
https://www.ncbi.nlm.nih.gov/pubmed/29454321
http://dx.doi.org/10.1186/s12885-018-4059-5

Ejemplares similares